Covaxin Effective Against COVID-19 Strains Found in India & UK: Bharat Biotech
Updated On Jul 07, 2021
Covaxin, India’s first indigenously developed COVID-19 vaccine by Bharat Biotech, has been found to be effective against the Indian and UK variants of the coronavirus. Bharat Biotech has recently informed that Covaxin produced neutralising titres against all key emerging variants tested, including the B.1.617 and B.1.1.7.
It must be noted that no difference in neutralization between B.1.1.7 (first found in the UK) and vaccine strain (D614G) was observed. However, a reduction in neutralisation by a factor of 1.95 was found against the B.1.617 variant compared to the vaccine strain (D614G).
Suchitra Ella, Joint Managing Director, Bharat Biotech, in her tweet, mentioned a study published in the Clinical Infectious Diseases medical journal that highlighted Covaxin’s ability to neutralize activity against emerging variants. The findings showed that despite the reduction, neutralizing titre levels with B.1.617 remain above levels expected to be protective.
The findings are from a study conducted by Bharat Biotech in collaboration with the National Institute of Virology - India Council of Medical Research.
At present, Covaxin is one of the main COVID-19 vaccines that are currently available in the country apart from Covishield and Sputnik V.
You may also like to read:
Disclaimer: This article is issued in the general public interest and meant for general information purposes only. Readers are advised not to rely on the contents of the article as conclusive in nature and should research further or consult an expert in this regard.